Steven D. Vold

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Researcher

University of Arkansas primary UAMS

Also affiliated: Northwestern University (1997–1998); University of North Texas (2020); Novartis (Switzerland) (2025); Carl Zeiss (Germany) (2025); RAND Corporation (2024); United States Food and Drug Administration (2024); Center for Devices and Radiological Health (2024); Thomas Jefferson University (2024); University of California, Los Angeles (2024); University of North Texas Health Science Center (2020); The University of Texas at San Antonio Health Science Center (2020); Texas A&M University System (2002–2008); Regeneron (United States) (2025); Volda University College (2016); New York Eye and Ear Infirmary (2020); Columbia University Irving Medical Center (2020); Temple College (2000–2008); Nassau University Medical Center (2020); Laredo Community College (2020); AbbVie (United States) (2025); Allergan (Ireland) (2025); Mercy Hospital Springfield (2020); Aerie Pharmaceuticals (United States) (2025); Sightsavers (2020); Control Vision (United States) (2013–2023); Johnson & Johnson (Germany) (2025); Creative Commons (2020); Williamson College (2020); Dean McGee Eye Institute (2014); Immunomedics (United States) (2020); Scott & White Memorial Hospital (2000–2008); Medical Prescription Services (2000); ATUM (United States) (2020); Allergan (United States) (2025); ZeptoMetrix (United States) (2011); Statistical Service (2020); Dermatology Specialists (2020); Ophthalmology Associates (United States) (2020); Université de Montréal (2020); Alcon (China) (2012); Rogers (United States) (2008–2010); University of Oklahoma (2014); Wills Eye Hospital (2024); Stanford University (2024)

Faculty Researcher

25 h-index 68 pubs 2,422 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

Steven D. Vold's research focuses on the investigation and treatment of glaucoma, particularly primary open-angle glaucoma. His work involves evaluating the efficacy and safety of various surgical interventions and medical devices designed to manage intraocular pressure and preserve visual function in patients with this condition.

Dr. Vold has published studies comparing surgical procedures such as ab-externo microshunt implantation against trabeculectomy. He has also investigated the outcomes of combined surgical techniques, including canaloplasty and trabeculotomy, often in conjunction with phacoemulsification for cataract removal. Furthermore, his research includes evaluating the impact of novel drug delivery systems, such as intraocular implants containing travoprost, on reducing the need for topical glaucoma medications and their associated burden on patients.

His scholarship includes 68 publications, with an h-index of 25 and over 2,300 citations. Dr. Vold has been recognized as a highly cited researcher. He remains active in his field, with recent publications extending into 2024 and beyond.

Metrics

h-index: 25
Publications: 68
Citations: 2,422

Selected Publications

One-Year Real-World Outcomes of Ab-Externo Gel Stent Placement From the EXPAND Study (2025)

Journal of Glaucoma 1 citation DOI OpenAlex
Twelve-month outcomes of an ab interno gelatin stent combined with cataract surgery or as a standalone procedure in pseudophakic eyes with open-angle glaucoma (2020)

Journal of Cataract & Refractive Surgery 7 citations DOI OpenAlex
Prioritizing Outcome Preferences in Patients with Ocular Hypertension and Open-Angle Glaucoma Using Best–Worst Scaling (2019)

Ophthalmology Glaucoma 15 citations DOI OpenAlex